18 June 2013
Keywords: phase, iii, results, xoma, cd5, plus, trial
Article | 12 December 1994
Results of a Phase III trial of Xoma's CD5 Plus product for the
treatment of graft-versus-host disease have been presented ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
17 June 2013
© 2013 thepharmaletter.com